RT Journal Article
SR Electronic
T1 Epidemiological and immunological features of obesity and SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.11.20229724
DO 10.1101/2020.11.11.20229724
A1 Nilles, Eric J
A1 Siddiqui, Sameed M
A1 Fischinger, Stephanie
A1 Bartsch, Yannic C
A1 de Saint Aubin, Michael
A1 Zhou, Guohai
A1 Gluck, Matthew
A1 Berger, Samuel
A1 Rhee, Justin
A1 Petersen, Eric
A1 Mormann, Benjamin
A1 Loesche, Michael
A1 Chen, Zhilin
A1 Yu, Jingyou
A1 Gebre, Makda
A1 Atyeo, Caroline
A1 Gorman, Matthew J
A1 Zhu, Alex Lee
A1 Burke, John
A1 Slein, Matthew
A1 Hasdianda, Mohammad A
A1 Jambaulikar, Guruprasad
A1 Boyer, Edward
A1 Sabeti, Pardis
A1 Barouch, Dan H
A1 Julg, Boris D
A1 Kucharski, Adam J
A1 Musk, Elon R
A1 Lauffenburger, Douglas A
A1 Alter, Galit
A1 Menon, Anil S
YR 2020
UL http://medrxiv.org/content/early/2020/11/13/2020.11.11.20229724.abstract
AB Obesity is established as a key correlate of severe SARS-CoV-2 outcomes. Multiple other epidemiological and immunological features are less well-defined including if obesity enhances susceptibility to SARS-CoV-2 infection, influences symptom phenotype, or impedes or alters the immune response to infection. Given the substantial global burden of obesity and given these uncertainties, we examined the epidemiology and immunology of obesity and SARS-CoV-2.Methods Industry employees were invited to participate in a prospective SARS-CoV-2 serology-based cohort study. Blood and baseline survey measures that included demographics, comorbidities, and prior COVID-19 compatible symptoms were collected. Serological testing and interim symptom reporting were conducted monthly. SARS-CoV-2 immunoassays included an IgG ELISA targeting the spike RBD, multiarray Luminex targeting 20 viral antigens, pseudovirus neutralization, and T cell ELISPOT assays. Unadjusted and adjusted analyses were used to identify differences in seroprevalence, clinical features, and immune parameters by BMI.Results Of 4469 individuals enrolled, 322 (7.21%) were seropositive. Adjusted seroprevalence was non-significantly lower with higher BMI. Obesity was associated with increased reporting of fever (OR 3.43 [95% CI 1.58-7.60]) and multiple other symptoms and aggregate measures. There were no identifiable differences in immune response between obese and non-obese individuals.Discussion We present benchmark data from a prospective serology-based cohort on the immunoepidemiology of BMI and SARS-CoV-2. Our findings suggest obesity is not linked to an increased risk of SARS-CoV-2 infection; that symptom phenotype is strongly influenced by obesity; and that despite evidence of obesity-associated immune dysregulation in severe COVID-19, there is no evidence of a muted or suppressed immune response across multiple immune measures among non-severe infections.Competing Interest StatementGA is a founder of Seromyx Systems Inc., a company developing platform technology that describes the antibody immune response. GAs interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. PS is a co-founder of, shareholder in, and advisor to Sherlock Biosciences, Inc, as well as a Board member of and shareholder in Danaher Corporation. MJG, SB, YH, JR, EP, BM, ASM and ERM are employees of Space Exploration Technologies Corp. All other authors have declared that no conflict of interest exists.Funding StatementWe acknowledge funding support from Space Exploration Technologies Corporation, the Brigham and Womens Department of Emergency Medicine, the Ragon Institute of MGH, MIT and Harvard, the Massachusetts Consortium on Pathogen Readiness (MassCPR), the NIH (3R37AI080289-11S1), FDA HHSF223201810172C, and the Gates foundation Global Health Vaccine Accelerator Platform funding. EJN is supported by the CDC (U01 GH002238). SMS was partially supported by the US Food and Drug Administration (HHSF223201810172C). DAL was partially supported by the National Institute for Allergy and Infectious Disease (U19 AI135995).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Western Institutional Review Board. The use of de-identified data and biological samples was approved by the Mass General Brigham Healthcare Institutional Review Board. All participants provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author, EJN. The data are not publicly available due to their containing information that could compromise the privacy of research participants.